180 related articles for article (PubMed ID: 14555862)
1. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
Perrone MR; Artesani MC; Viola M; Gaeta F; Caringi M; Quaratino D; Romano A
Int Arch Allergy Immunol; 2003 Sep; 132(1):82-6. PubMed ID: 14555862
[TBL] [Abstract][Full Text] [Related]
2. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
[TBL] [Abstract][Full Text] [Related]
4. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
[TBL] [Abstract][Full Text] [Related]
5. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
[TBL] [Abstract][Full Text] [Related]
6. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs.
Pacor ML; Di Lorenzo G; Biasi D; Barbagallo M; Corrocher R
Clin Exp Allergy; 2002 Mar; 32(3):397-400. PubMed ID: 11940070
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs.
Quaratino D; Romano A; Di Fonso M; Papa G; Perrone MR; D'Ambrosio FP; Venuti A
Ann Allergy Asthma Immunol; 2000 Jun; 84(6):613-7. PubMed ID: 10875490
[TBL] [Abstract][Full Text] [Related]
8. Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Di PR; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2002 Mar; 88(3):331-4. PubMed ID: 11926629
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs.
Viola M; Quaratino D; Gaeta F; Caringi M; Valluzzi R; Caruso C; Volpetti S; Romano A
Int Arch Allergy Immunol; 2005 Jun; 137(2):145-50. PubMed ID: 15897671
[TBL] [Abstract][Full Text] [Related]
10. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Stevenson DD; Simon RA
J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
[TBL] [Abstract][Full Text] [Related]
11. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Bavbek S; Celik G; Pasaoglu G; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
[TBL] [Abstract][Full Text] [Related]
12. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
[TBL] [Abstract][Full Text] [Related]
13. Safety of selective cyclooxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions.
Quiralte J; Sáenz de San Pedro B; Florido JJ
Ann Allergy Asthma Immunol; 2002 Jul; 89(1):63-6. PubMed ID: 12141722
[TBL] [Abstract][Full Text] [Related]
14. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Quiralte J; Delgado J; Sáenz de San Pedro B; López-Pascual E; Nieto MA; Ortega N; Florido JF; Conde J
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
[TBL] [Abstract][Full Text] [Related]
15. [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs].
Ahlbach S; Usadel KH; Kaufmann R; Boehncke WH
Med Klin (Munich); 2003 Apr; 98(5):242-4. PubMed ID: 12721666
[TBL] [Abstract][Full Text] [Related]
16. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
17. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
Kruse R; Ruzicka T; Grewe M
Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
[TBL] [Abstract][Full Text] [Related]
18. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma.
Martín-García C; Hinojosa M; Berges P; Camacho E; García-Rodriguez R; Alfaya T; Iscar A
Chest; 2002 Jun; 121(6):1812-7. PubMed ID: 12065343
[TBL] [Abstract][Full Text] [Related]
19. Etoricoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs.
Viola M; Quaratino D; Gaeta F; Caruso C; Valluzzi R; Romano A
Int Arch Allergy Immunol; 2007; 143(2):103-8. PubMed ID: 17228166
[TBL] [Abstract][Full Text] [Related]
20. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
